secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001104659-24-037296
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio reports record 2023 revenue $58.5M (+41% YoY); guides FY2024 $74-76M
-----------------------------------------------------------------------------

- Q4 revenue $17.0M (+46% YoY); full-year revenue $58.5M (+41% YoY).
- Net loss $12.9M in Q4, $46.7M for FY 2023; cash $46.7M at year-end.
- FY 2024 revenue guidance $74-76M (27-30% YoY growth).
- Launched LIQUIFIX FIX8 and Precision, FDA-approved liquid adhesive for hernia mesh fixation.
- Sold NIVIS distribution rights to MiMedx for $8-12M cash consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/0001104659-24-037296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/tm249241d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer